Grants for Research Projects Aligned with MAPS' Mission (by invitation only) is sponsored by Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS funds and supports independent research projects worldwide that align with its mission of advancing the collective understanding of the potential applications and risks associated with psychedelics.

Advancing Research – Multidisciplinary Association for Psychedelic Studies – MAPS MAPS spent decades developing MDMA-assisted therapy as a means to Set the Setting for the clinical utilization of psychedelic-assisted therapies. With the road paved for the next generation of research and drug development, MAPS now stewards the research landscape we helped cultivate.

We are dedicated to fostering new research directions that Prioritize Public Benefit , supporting international researchers and pilot programs, and ensuring the accessibility and culturally appropriate integration of psychedelics as a tool for individual and community wellness. We practice Open Science, Open Books, and center research that contributes to knowledge in the public domain.

Click the button below to learn more about current MAPS research initiatives.

Tenets of Research Stewardship We fill gaps in the ecosystem to Prioritize Public Benefit , rather than profit We accelerate new research to inform public knowledge and sensible policy reform We maximize access domestically and globally to work toward Healing for All We Accelerate Psychedelic Research MAPS is proud to fund and support researchers worldwide to advance our collective understanding of the potential applications and risks associated with psychedelics.

We award grants and provide fiscal sponsorship, by invitation only, to independent research projects aligned with MAPS’ mission. Click here to learn more about our Fiscal Sponsorship program. MAPS initiates projects that open new research directions or set regulatory precedents.

We strive to lay the groundwork for new or challenging research fields by fostering studies that expand our collective knowledge of the possible uses and delivery of psychedelics. MAPS provides international therapist education programs to equip care providers with the fundamentals and best practices of psychedelic-assisted therapies to increase awareness and activate potential research initiatives across the globe.

Click here for more information on our International Therapist Education Program. MAPS is building the capacity to expand our regulatory, protocol, and diversity consultation services to select independently funded researchers and MAPS grantees. MDMA-assisted therapy can help heal psychological disorders and trauma.

Learn about our studies and find resources like our Investigator’s Brochure and treatment manual. Cannabis treatment shows progress for symptoms of PTSD in war veterans. A pilot study of LSD-assisted therapy demonstrated a reduction in anxiety among people with a life-threatening illness.

New Zealand and Mexico studies show ibogaine can help opioid and alcohol addiction. Our study suggested ayahuasca-assisted therapy may be useful for treating drug addiction. See what’s happening in today’s psychedelic science news.

placeholder thumbnail April 18, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) issued the following statements from Co-Executive Directors Betty Aldworth and Ismail L. Ali, J. D.

, on today’s Executive … placeholder thumbnail February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted … placeholder thumbnail On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review.

… placeholder thumbnail On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA).

The … placeholder thumbnail December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense … The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification.

Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment … placeholder thumbnail San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy … placeholder thumbnail August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization … placeholder thumbnail WASHINGTON, DC (August 14, 2025) — One year after the FDA’s denial of the New Drug Application for MDMA-assisted therapy for PTSD, the Multidisciplinary Association for Psychedelic Studies (MAPS) has … FOR IMMEDIATE RELEASE: November 20, 2024 The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase … Learn about the many ways to join the psychedelic community, from membership, volunteering, and careers to learning how to get involved with psychedelic-assisted therapy.

Download our Integration Guide Just enter your email in order to download our Integration Guide